Is Mettler-Toledo profitable in 2026?

Yes. Mettler-Toledo posted Q1 2026 adjusted EPS of $8.91, beating consensus of $8.70, on revenue of $947.13 million, up 7.2% year over year, as of March 31, 2026. Q4 2025 adjusted EPS was $13.36, also beating consensus.

Could AI replace Mettler-Toledo's business?

Not the core. AI is automating visual inspection tasks via products like the X56 DXD+ x-ray system launched July 17, 2026, but regulated calibration, GMP/21 CFR Part 11 compliance, and a roughly 9,000-person global service network remain human-delivered and hard to replicate.

Is Mettler-Toledo laying off workers?

No. Headcount rose to 18,100 employees as of December 31, 2025, up 4.62% from 17,300 in 2024, per company-reported figures, indicating continued hiring rather than layoffs.

Who owns Mettler-Toledo International?

It is an independent public company trading as NYSE: MTD, with no parent or acquirer. Market capitalization was roughly $26 to $27 billion as of July 24, 2026, and the company was actively buying back its own shares, targeting $825 to $875 million in 2026 repurchases.

Who is Mettler-Toledo's biggest competitor?

Sartorius AG is the most frequently cited direct rival, competing in lab balances via its Cubis platform and in bioprocessing, per a June 18, 2026 competitive analysis. Thermo Fisher Scientific and Danaher are named as larger adjacent-scale competitors.

Why is Mettler-Toledo's stock under pressure in 2026?

Analysts cut price targets in 2026, including JPMorgan to $1,200 from $1,413, citing soft organic growth (only about 1% ex-acquisitions in Q1 2026) and new Section 301 tariffs of 10 to 12.5% effective July 24, 2026 adding margin drag.

Biotech tools companies · United States

Mettler-Toledo International

mt.com ↗

Maker of precision lab balances, scales, and analytical instruments for pharma, food, and industry.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from July 30-31, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report and call

The call

Growth has slowed to low single digits under tariff pressure, but no rival has yet pulled customers away from its certified, service-locked instrument base.

Mettler-Toledo sells weighing scales, laboratory instruments, and inspection equipment to pharma, food, and manufacturing companies worldwide. The company is hard to replace because its scales and systems are locked into customers' regulatory paperwork and compliance rules (government agencies require them to use certified, validated equipment), and Mettler-Toledo's army of 9,000 service technicians keeps customers sticky through ongoing calibration contracts that bring in more than half the profit on core products. No major rival has stolen meaningful sales from its core business. The big question is whether new US tariffs hitting in mid-2026 and slower growth in China will squeeze profit margins enough to hurt the stock, even though the company itself will survive.

Why

AI pressure: None apparent. AI mostly feeds their instruments as software add-ons for data capture, not a force eating their hardware business. Could AI do the core job? Unlikely.

Bigger players: Sartorius and Thermo Fisher Scientific. Both sell competing balances, analytics, and lab gear today, but neither has visibly pulled share from Mettler-Toledo's core lines. Could a giant copy it? No, they are blocked.

What protects it. Metrological certification, GMP/21 CFR Part 11 workflow lock-in, and a 9,000-person service network keep customers renewing calibration contracts.

What would change this call

Q2 2026 earnings (July 30, 2026) organic growth rate vs. ~4% FY guidance. Growth below guidance would suggest demand or share erosion beyond tariff effects.
Service revenue growth rate and attach rate (%) reported in quarterly filings through 2026. Attach rate falling below ~40-50% would signal weakening customer lock-in.
Sartorius or Thermo Fisher announcing certified, service-backed balance or inspection products with named account wins from Mettler-Toledo. Would be first direct evidence of a competitor taking core-line customers.

Key numbers

Q1 2026 revenue $947.13M, up 7.2% YoY (2026-03-31)
Q4 2025 revenue $1.1B, up 8% YoY (2025-12-31)
FY2026 guidance: ~4% local-currency growth, EPS $46.30-$46.95 (2026)

Named risks

New Section 301 tariffs (10-12.5%, effective July 24, 2026) stacking on prior 90-190bps margin drag. Severity: high
Organic growth ex-acquisitions slowed to about 1% in Q1 2026, below FY2026 guided 4% local-currency growth. Severity: medium
Removal from Russell 1000 Dynamic Index (July 9, 2026) reflecting weaker growth outlook could pressure passive fund flows. Severity: low
China trade escalation could delay GLP-1 manufacturing and pharmacopoeia-driven lab equipment demand in H2 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Sartorius AG	contesting	Direct rival in lab balances (Cubis) and bioprocessing, named June 18, 2026
Thermo Fisher Scientific	contesting	Named alongside MTD in pharmaceutical inspection machines market report, August 2025
Danaher	contesting	Larger diversified life-science conglomerate with scale-based pricing pressure, per 2026 peer comparison
Shimadzu and Ohaus	contesting	Named as lab balance competitors at lower and mid price tiers, January 2026 industry report

Questions people ask

Is Mettler-Toledo profitable in 2026?: Yes. Mettler-Toledo posted Q1 2026 adjusted EPS of $8.91, beating consensus of $8.70, on revenue of $947.13 million, up 7.2% year over year, as of March 31, 2026. Q4 2025 adjusted EPS was $13.36, also beating consensus.
Could AI replace Mettler-Toledo's business?: Not the core. AI is automating visual inspection tasks via products like the X56 DXD+ x-ray system launched July 17, 2026, but regulated calibration, GMP/21 CFR Part 11 compliance, and a roughly 9,000-person global service network remain human-delivered and hard to replicate.
Is Mettler-Toledo laying off workers?: No. Headcount rose to 18,100 employees as of December 31, 2025, up 4.62% from 17,300 in 2024, per company-reported figures, indicating continued hiring rather than layoffs.
Who owns Mettler-Toledo International?: It is an independent public company trading as NYSE: MTD, with no parent or acquirer. Market capitalization was roughly $26 to $27 billion as of July 24, 2026, and the company was actively buying back its own shares, targeting $825 to $875 million in 2026 repurchases.
Who is Mettler-Toledo's biggest competitor?: Sartorius AG is the most frequently cited direct rival, competing in lab balances via its Cubis platform and in bioprocessing, per a June 18, 2026 competitive analysis. Thermo Fisher Scientific and Danaher are named as larger adjacent-scale competitors.
Why is Mettler-Toledo's stock under pressure in 2026?: Analysts cut price targets in 2026, including JPMorgan to $1,200 from $1,413, citing soft organic growth (only about 1% ex-acquisitions in Q1 2026) and new Section 301 tariffs of 10 to 12.5% effective July 24, 2026 adding margin drag.

Timeline

2026-07-24New US Section 301 tariffs of 10-12.5% on 60 countries including China take effect
2026-07-17Launched X56 DXD+ dual-energy AI x-ray inspection system with AMD Pro software
2026-07-09Removed from Russell 1000 Dynamic Index amid soft organic growth outlook
2026-05-07Reported Q1 2026 revenue of $947.13 million, up 7.2% YoY, beating consensus
2026-05-06Unveiled AI-enabled inspection systems at Interpack 2026
2026-02-06Reported Q4 2025 revenue of $1.1 billion, up 8% YoY, EPS beat
2022Introduced AIWizard deep-learning tool for DSC thermal analysis interpretation

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE